PureTech Health plc

PureTech Health plc is a biotechnology and pharmaceutical company based in Boston, Massachusetts, incorporated in 2015. It develops and commercializes therapeutic solutions in the United States. Its pipeline includes LYT-100, a Phase 3-ready candidate for idiopathic pulmonary fibrosis and other fibrotic lung diseases, and LYT-200, a fully human IgG4 monoclonal antibody. The company also develops SPT-300, an oral prodrug of allopregnanolone for anxious depression, hydrogels for oral peptide therapeutics, and oral therapies based on defined bacterial consortia in Phase 3 clinical development.